MDXG Rentabilitas dodolan miturut bathi reged MiMedx Group

Simbol resmi perusahaan MiMedx Group (MDXG)

MiMedx Group, Inc. (MDXG) dominates the regenerative tissue healing product segment thanks to strong patent protection. The gross profit margin illustrates this resilience, where 77.00 is the current level of the metric. Stable revenue is driven by the sale of matrices to hospitals, although growth is constrained by cleanroom costs. US-based capacities and unique placental drug technologies guarantee production reliability.

MiMedx (MDXG): Rentabilitas reged saka 04.07.2022 nganti 20.11.2026

Rincian analitis lan laporan data perusahaan mimedx.com (MDXG)

- kuotasi saiki lan rata-rata prakiraan nilai:
Pambiji fundamental:MDXG MiMedx
Produk seri MiMedx Group, Inc.

Gross margin is calculated as the ratio of the difference between revenue and cost of goods sold to total sales, determining direct production efficiency and capital safety margins. The growth in gross profit margin for MiMedx Group, Inc. (MDXG) reflects the high added value of biologics amid expanding demand in the regenerative medicine and diabetic complication therapy segments.